

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF COLUMBIA

FILED

JUL 27 2009

Clerk, U.S. District and
Bankruptcy Courts

JURIDICAL FOUNDATION THE CHEMO-SERO-
THERAPEUTIC RESEARCH INSTITUTE
6-1, Okubo 1-chome
Kumamoto-shi
Kumamot-ken, Japan 860-8568

Plaintiff,

v.

Case: 1:09-cv-01383

Assigned To : Leon, Richard J.

Assign. Date : 7/27/2009

Description: General Civil

HON. JOHN J. DOLL
Acting Under Secretary of Commerce for Intellectual
Property and Acting Director of the United States
Patent and Trademark Office
Madison Building
600 Dulany Street
Alexandria, VA 22314

Defendant.

COMPLAINT

Plaintiff Juridical Foundation The Chem-Sero-Therapeutic Research Institute ("JFCRI"),
for its complaint against defendant, the Honorable John J. Doll, states as follows:

1. This is an action by the owner of United States Patent No. 7,482,436 seeking review of inaccurate and erroneous patent term adjustment calculations made by the United States Patent and Trademark Office ("USPTO"). Specifically, this is an action by Plaintiffs under 35 U.S.C. § 154(b)(4)(A) seeking a judgment that the patent term adjustment of 427 days calculated by the USPTO for the '436 patent should be corrected to 761 days.
2. This action arises under 35 U.S.C. § 154 and the Administrative Procedure Act, 5 U.S.C. §§ 701-706.

I. THE PARTIES

3. Plaintiff JFCRI is a company operating under the laws of Japan. JFCRI is located at 6-1, Okubo 1-chome, Kumamoto-shi, Kumamoto-ken, Japan, 860-8568.
4. Defendant John J. Doll is the Acting Under Secretary of Commerce for Intellectual Property and Acting Director of the United States Patent and Trademark Office. Defendant is sued in his official capacity.

II. JURISDICTION AND VENUE

5. This Court has jurisdiction over this action and is authorized to issue the requested relief to Plaintiffs pursuant to 28 U.S.C. §§ 1331, 1338(a) and 1361; 35 U.S.C. § 154(b)(4)(A) and 5 U.S.C. §§ 701-706.
6. Venue is proper in this district pursuant to 35 U.S.C. § 154(b)(4)(A).
7. This Complaint is being timely filed in accordance with 35 U.S.C. § 154(b)(4)(A) and FRCP 6(a)(3).

III. BACKGROUND

8. The '436 patent issued to Kazuhisa Sugimura, Kazuyuki Yoshizaki, Toshihiro Nakashima, and Takumi Sasaki on January 27, 2009, based on patent application number 10/526,072 which was a National Stage Application of PCT No. PCT/JP03/010923, filed on August 28, 2003, claiming priority to Japanese Patent Application No. 2002-253036, filed August 30, 2002. The '436 patent is attached hereto as Exhibit A.
9. Plaintiff JFCRI is the assignee of the '436 patent, as evidenced by records recorded in the USPTO, and is the real party in interest in this case. Recordation of the Assignment was electronically filed in the United States Patent and Trademark Office on July 27, 2009.

10. When the USPTO issued the '436 patent on January 27, 2009, it erroneously calculated the entitled patent term adjustment ("PTA") for the '436 patent as 427 days. Had the USPTO calculated the PTA properly, the '436 patent would be entitled to 761 days of patent term adjustment.
11. The errors in the USPTO's patent term adjustment calculations are detailed in a recent order from the U. S. District Court for the District of Columbia in an action titled *Wyeth v. Dudas*, 580 F. Supp. 2d 138 (D.D.C. Sept. 30, 2008), where the Court granted summary judgment against the USPTO, holding that the USPTO's patent term adjustment calculation methodology was erroneous as a matter of law and inconsistent with the Patent Statute.
12. The correct patent term adjustment methodology identified in the prior *Wyeth v. Dudas* action governs the USPTO's calculation of patent term adjustment for Plaintiff's '436 patent.

IV. COUNT I: U.S. PATENT NO. 7,482,436

13. Plaintiff incorporates by reference the allegations in paragraphs 1-13 above, as if fully set forth herein.
14. During prosecution of the '436 patent, the patent owner accrued 427 days of PTA under 35 USC § 154(b)(1)(A), and accrued 334 days of PTA under 35 USC 154(b)(1)(B).
15. Under the USPTO's interpretation of 35 USC § 154, all PTA accrued under 35 U.S.C. § 154(b)(1)(A) and all PTA accrued under 35 USC § 154(b)(1)(B) overlap and, thus, it has been the USPTO position that a patent holder is only eligible for the larger of these two amounts of PTA, 427 days. For the '436 patent, the USPTO erroneously limited the PTA

for the '436 patent to 427 days (*see* calculation in paragraph 21, below), as shown on the face of the '436 patent.

16. In view of a recent decision from this Court (*Wyeth v. Dudas, supra*), all days on which 35 USC 154(b)(1)(A) or 35 USC 154(b)(1)(B) apply should accrue patent term adjustment for the '436 patent, except for any days that are actual calendar days overlap.
17. Each day from the day after April 28, 2006 (14 months from the Filing or 371(c) date) through to the issuance of the First Office Action on June 29, 2007, qualify for patent term adjustment under 35 U.S.C. § 154(b)(1)(A), a total of 427 days.
18. Furthermore, each day from the day after February 28, 2008 (3 years after the national stage commencement date) through to the date of issue on January 27, 2009, qualify for patent term adjustment under 35 U.S.C. § 154(b)(1)(B), a total of 334 days.
19. Under the interpretation of this Court (*Wyeth v. Dudas, supra*), only period of actual calendar days overlap between the time periods of delay calculated under 35 U.S.C. § 154(b)(1)(A) and 35 U.S.C. § 154(b)(1)(B) are to be considered as overlap. In this case, there are no days of overlap, as all of the days of delay under § 154(b)(1)(A) are prior to February 28, 2008, the date that is three years after the filing or national stage commencement date, which is the date that the delay under § 154(b)(1)(B) commenced. Thus, the total USPTO prosecution delay is accordingly $427 + 334 = 761$ days, minus any period attributed to disclaimed term or applicant's delay, 35 U.S.C. § (154(b)(2)(B) or (C).
20. The USPTO correctly attributed a total of 0 days to applicant's prosecution delay under 35 USC 154(b)(2)(B) or (C).

21. Under the USPTO's interpretation, the USPTO had calculated an erroneous patent term adjustment of $427-0=427$ days.
22. It is accordingly believed that the overall patent term adjustment accrued by the patent holder is $427+334-0 = 761$ days, and the patent holder accordingly requests $761 - 427$ 334 **ADDITIONAL** days of patent term adjustment.

WHEREFORE, Plaintiff respectfully prays that this Court:

- A. Issue an Order changing the period of patent term adjustment for the '436 patent term from 427 days to 761 days and requiring Defendant to alter the terms of the '436 patent to reflect the 761 days of actual patent term adjustment due the '436 patent.
- B. Grant such other and further relief as the nature of the case may admit or require and as may be just and equitable.

Respectfully submitted,
JURIDICAL FOUNDATION THE CHEM-
SERO-THERAPEUTIC RESEARCH
INSTITUTE

Dated: July 27, 2009

By:



Roger L. Browdy (DC Bar No. 164,251)
Ronni S. Jillions (DC Bar No. 375,817)
BROWDY AND NEIMARK, P.L.L.C.
624 Ninth Street, N.W.
Washington, DC 20001
Tel.: (202) 628-5197
Fax: (202) 737-3528
Email: rlbrowdy@browdyneimark.com
rsjillions@browdyneimark.com

Attorneys for Plaintiff

BROWDY AND NEIMARK, P.L.L.C.
624 Ninth Street, NW
Washington, DC 20001
(202) 202-628-5197

G:\NTU\FCRivDoll\Sugimura4\2009-07-27Complaint.doc

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF COLUMBIA

JURIDICAL FOUNDATION THE CHEMO-SERO-)
THERAPEUTIC RESEARCH INSTITUTE)

6-1, Okubo 1-chome)
Kumamoto-shi)
Kumamot-ken, Japan 860-8568)

Plaintiff,)

v.)

Civil Action No. ----

HON. JOHN J. DOLL)
Acting Under Secretary of Commerce for Intellectual)
Property and Acting Director of the United States)
Patent and Trademark Office)
Madison Building)
600 Dulany Street)
Alexandria, VA 22314)

Defendant.)

Exhibit A

09 1383

FILED

JUL 27 2009

Clerk, U.S. District and
Bankruptcy Courts



US007482436B2

(12) **United States Patent**
Sugimura et al.

(10) **Patent No.:** US 7,482,436 B2
(45) **Date of Patent:** Jan. 27, 2009

(54) **HUMAN ANTIHUMAN INTERLEUKIN-6
ANTIBODY AND FRAGMENT OF ANTIBODY**

(75) Inventors: **Kazuhisa Sugimura**, Kagoshima (JP);
Kazuyuki Yoshizaki, Ashiya (JP);
Toshihiro Nakashima, Kikuchi-gun
(JP); **Takumi Sasaki**, Kikuchi-gun (JP)

(73) Assignee: **Juridical Foundation The
Chemo-Sero-Therapeutic Research
Institute**, Kumamoto-Ken (JP)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 427 days.

(21) Appl. No.: 10/526,072

(22) PCT Filed Aug. 28, 2003

(86) PCT No.: PCT/JP03/10923

§ 371 (c)(1),
(2), (4) Date: Feb. 28, 2005

(87) PCT Pub. No.: WO2004/020633

PCT Pub. Date: Mar. 11, 2004

(65) **Prior Publication Data**

US 2006/0240012 A1 Oct. 26, 2006

(30) **Foreign Application Priority Data**

Aug. 30, 2002 (JP) 2002-253036

(51) **Int. Cl.**
C07K 16/24 (2006.01)

(52) **U.S. Cl.** 530/388.15; 530/388.23

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U S. PATENT DOCUMENTS

5,959,085 A * 9/1999 Garrone et al. 530/387.3
2004/0071706 A1 * 4/2004 Ito et al. 424/145.1

FOREIGN PATENT DOCUMENTS

WO WO 2005/105998 A 11/2005

OTHER PUBLICATIONS

Janeway et al., *Immunobiology*, 5th Ed., Garland Science, pp 94-105
(2001) *
Vajdos et al., *J Mol Biol* Jul. 5, 2002;320(2) 415-28 *
Rudikoff et al, *Proc Natl Acad Sci. USA*, 79:1979-1983 *
Colman P M., *Research in Immunology*, 145 33-36, 1994. *
Chien et al., *Proc Natl Acad Sci U S A* Jul. 1989;86(14):5532-6 *
Rose-John et al., *J Leukoc Biol*, Aug. 2006;80(2):227-36 *
Matsuda et al., *J Immunol* Jan. 1, 1989;142(1):148-52. *
Chow et al., *Biochemistry* Jun. 26, 2001;40(25):7593-603. *

Dictionary of Immunology, 1st edition, p. 49. 1993 (2nd edition, p. 60)

S. Akira et al.; "Interleukin-6 in Biology and Medicine": *Advances in Immunology*, vol. 54, pp. 1-78; 1993

R. Gejma et al.; "Human Single-chain Fv (scFv) Antibody Specific to Human IL-6 with the Inhibitory Activity on IL-6-signaling", *Human Antibodies*, vol. 11(4), pp. 121-129, 2002

T. Hirano et al., "Interleukin-6: Possible Implications in Human Diseases", *Res. Clin. Lab.*, vol. 19(1), pp. 1-10, 1989

B. Krebs et al., "Recombinant Human Single Chain Fv Antibodies Recognizing Human Interleukin-6", *The Journal of Biological Chemistry*, vol. 273(5), pp. 2858-2865; 1998

J. D. Marks et al.; "By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage"; *Journal Molecular Biology*, vol. 222(3), pp. 581-597; 1991.

M. Mihara et al., "Interleukin-6 (IL-6) Induces the proliferation of Synovial Fibroblastic Cells in the Presence of Soluble IL-6 Receptor", *British Journal of Rheumatology*, vol. 34(4), pp. 321-325, 1995

M. Mihara et al., "Humanized Antibody to Human Interleukin-6 Receptor Inhibits the Development of Collagen Arthritis in Cynomolgus Monkeys", *Clinical Immunology*, vol. 98(3), pp. 319-326, 2001.

S. Monier et al.; "Growth Factor Activity of IL-6 in the Synovial fluid of patients with rheumatoid arthritis", *Clinical and Experimental Rheumatology*, vol. 12(6), pp. 595-602, 1994.

F. Montero-Julian et al., "Pharmacokinetic Study of Anti-Interleukin-6 (IL-6) Therapy with Monoclonal Antibodies. Enhancement of IL-6 Clearance by Cocktails of Anti-IL-6 Antibodies", *Blood*, vol. 85, pp. 917-924; 1995

N. Nishimoto et al., "Clinical Application of Interleukin-6 receptor antibody", *Japanese Society for Immunology*, vol. 20 (2), pp. 87-94, 1997

A. Ogata et al.; "Advances in Interleukin-6 Therapy"; *Clinical Pathology*, vol. 47(4), pp. 321-326, 1999.

K. Sato et al., "Humanization of an anti-human IL-6 mouse monoclonal antibody glycosylated in its heavy chain variable region", *Human Antibody Hybridomas*, vol. 7(4), pp. 175-193; 1996.

D. Wendling et al., "Treatment of Severe Rheumatoid Arthritis by anti-interleukin 6 monoclonal antibody"; *Journal Rheumatology*, vol. 20(2); pp. 259-262; 1993

J. Wydenes et al. "Human Recombinant Dimeric IL-6 Binds to Its Receptor as Detected by Anti-IL-6 Monoclonal Antibodies"; *Molecular Immunology*, vol. 28(11), pp. 1183-1192; 1991

G. Vreugdenhil et al.; "Anaemia of chronic disease in rheumatoid arthritis"; *Rheumatol Int.*, vol. 10 (3), pp. 127-130; 1990

* cited by examiner

Primary Examiner—Michail A. Belyavskyi

Assistant Examiner—Zachary Skelding

(74) **Attorney, Agent, or Firm**—Browdy and Neimark, P.L.L.C.

(57) **ABSTRACT**

A substance effective for treating immunopathy where interleukin 6 (IL-6) is involved is provided. A human anti-human IL-6 antibody and a human anti-human IL-6 antibody fragment having a high affinity to human IL-6 were obtained using phage antibody technique. The antibody and antibody fragment are expected to be useful as a medicament for treating inflammation and immunopathy caused by IL-6.

2 Claims, 3 Drawing Sheets


U.S. Patent

Jan. 27, 2009

Sheet 1 of 3

US 7,482,436 B2

Fig. 1




U.S. Patent

Jan. 27, 2009

Sheet 2 of 3

US 7,482,436 B2

Fig. 2



Immobilized Protein	Ligand	$k_{\text{ass}}/10^5$ ($\text{sec}^{-1}\text{M}^{-1}$)	$k_{\text{diss}}/10^{-3}$ (sec^{-1})	K_D (nM)
Human IL-6	IL6gk3-2	0.6 ± 0.34	0.8 ± 0.34	13


U.S. Patent

Jan. 27, 2009

Sheet 3 of 3

US 7,482,436 B2

Fig. 3



US 7,482,436 B2

1

HUMAN ANTIHUMAN INTERLEUKIN-6 ANTIBODY AND FRAGMENT OF ANTIBODY

TECHNICAL FIELD

The present invention relates to a human anti-human interleukin-6 (hereinafter referred to as "IL-6") antibody that binds to human IL-6 to thereby block binding between IL-6 and its receptor, a fragment of said antibody, and a gene fragment encoding the same. The antibody and a fragment thereof according to the present invention are expected to be useful as a medicament for treating inflammation and immunopathy caused by IL-6.

BACKGROUND ART

IL-6 is a glycoprotein with a molecular weight of 21,000 that is produced from T cells, macrophages, fibroblasts, muscular cells and the like when stimulated with a mitogen, viral infection, or IL-1. Human IL-6 consists of 184 amino acids and its gene is present on the 7th chromosome. IL-6 has diverse biological activities including (1) induction of cellular proliferation (hybridomas, T cells, keratinocytes, renal mesangial cells), (2) inhibition of cellular proliferation (myelogenous leukemia cell lines, malignant melanoma cell lines), and (3) induction of cellular differentiation and induction of production of cellular specific proteins (neural differentiation of melanocytoma cell lines, differentiation of killer T cells, maturation of megakaryocytes, differentiation into macrophages of myelogenous leukemia cell lines, antibody production of B cells, production of acute phase proteins in hepatocytes). Due to its diverse biological activities, it has been indicated that IL-6 may be relevant to some diseases. In recent years, it is known that IL-6 is involved in onset of diseases including (1) rheumatoid arthritis, atrial myxoma, Castleman disease, hypergammaglobulinemia or autoimmune symptoms in AIDS, (2) mesangial nephritis, (3) psoriasis, and (4) Kaposi sarcoma in AIDS. Recently, it is also known that a large quantity of IL-6 is produced from the skeletal muscle immediately after physical practice, which stimulates hypothalamus to secrete various neurohormones to thereby affect the immune system (Dictionary of Immunology, 1st ed., p. 49, 1993).

Among the diseases where IL-6 is involved, rheumatoid arthritis (RA) afflicts about 7×10^5 people all over the country in Japan with gradual increase and together with increase in the number of aged patients is becoming a social problem (Ogata A. et al., Rinsho Byori (Clinical Pathology), 1999 April; 47 (4): 321-326 [Advances in interleukin-6 therapy]).

The cause of RA is not known. RA, an autoimmune disease wherein an autoimmune reaction within the articular cavity has continued and became chronic, is assigned as one of inveterate specific diseases. Relevancy of RA to IL-6 has been investigated to reveal that a large quantity of IL-6 is present in joint fluid from RA patients and that IL-6 is involved not only in induction of inflammation but also in proliferation of fibroblasts in the synovial membrane. There is also possibility that IL-6 may accelerate production of autoantibody (Nishimoto N. et al., Clinical application of interleukin-6 receptor antibody, transactions of Japanese Society for Immunology 1997; 20: 87-94).

Accordingly, anti-IL-6 antibody that inhibits the biological activities of IL-6 would be a candidate of a nosotropic medicament for treating several immunopathies including RA and is practically under investigation (Mihara M. et al., *Br. J. Rheumatol.* 1995 April; 34(4): 321-325; Mihara M. et al., *Clin Immunol.* 2001, 98: 319-326).

2

DISCLOSURE OF THE INVENTION

(Technical Problems to be Solved by the Invention)

For RA patients, a wide variety of treatments have been applied including drug therapy with non-steroidal antiinflammatory, analgesic agents, steroidal agents, immunosuppressive agents or antimetabolites, and surgical therapy such as artificial joint, depending on a disease stage of patients. However, these therapies are not eradicated for RA but there are problems of adverse side effects due to application of therapies for a long period of time with a large amount of drugs. IL-6 plays a role in enhancement of inflammation and hence is a major cause of pain RA patients suffered from. It has been indicated therefore that inhibition of the IL-6 activity would alleviate the pain. As a candidate, a humanized anti-IL-6 antibody has been investigated (Montero-Julian F. A. et al., *Blood* 1995 February 15; 85(4): 917-24; Monier S. et al., *Clin. Exp. Rheumatol.* 1994 November-December; 12(6): 595-602; Wendling D. et al., *J. Rheumatol.* 1993 February; 20(2): 259-62).

On the other hand, IL-6 has an activity of a growth factor to myeloma cells (Dictionary of Immunology, 1st ed., p. 49, 1993; aforementioned) and hence causes a problem that, even if hybridomas producing an antibody that binds to IL-6 with high affinity were obtained, their proliferation is hampered through neutralization of IL-6 in the culture medium by the produced antibody and as a result obtaining an anti-IL-6 antibody with high affinity has been difficult. Sato et al. reported that an anti-human IL-6 antibody obtained from mice exhibited high affinity of 11 nM but also with a high dissociation rate of 3×10^{-2} sec. (Sato K. et al., *Hum. Antibodies Hybridomas* 1996; 7(4): 175-83). With such an antibody having a high dissociation rate as obtained by the prior art techniques, maintenance of a high concentration of the antibody was necessary for inhibiting the IL-6 activity. Much less, an antibody with such an activity is never known that is a wholly human antibody.

Besides, unlike a wholly human antibody, a possibility could not be denied that administration of a humanized antibody to patients would lead to production in patients of an antibody (blocking antibody) that inhibits the activity of the anti-IL-6 antibody.

(Means to Solve the Problems)

Under the circumstances, the present inventors devised a screening system with the phage antibody technique to thereby obtain a wholly human anti-human IL-6 antibody single chain Fv (scFv) molecule and elucidated VH and VL chains of said antibody. The present inventors further analyzed the properties of said scFv to reveal that said scFv exhibited a significantly lower association rate as compared to those of the conventional antibodies against human IL-6 obtained from a variety of animals (in the order of 10^{-3} sec; dissociation rate being about 40-folds lower than that of conventional ones), had an equivalent or higher affinity to IL-6 as compared to the conventional antibodies, and inhibited proliferation of IL-6 dependent cell lines in a concentration dependent manner.

(More Efficacious Effects than Prior Art)

It is expected that the use of such an antibody that is wholly derived from human and has a high affinity to IL-6 would exert therapeutic effects with a lower antibody concentration than a chimeric antibody or a humanized antibody to thereby produce only an extremely low level of anti-idiotypic antibody against said antibody and hence would provide an anti-human IL-6 antibody drug that will exhibit excellent therapeutic

US 7,482,436 B2

3

effects as an anti-IL-6 antagonist for treating autoimmune diseases such as IL-6 dependent leukemia and rheumatoid arthritis. The antibody according to the present invention is also expected for use as a medicament for treating acute inflammation with reduced side effects and with potent activity.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 is a graph showing the results of ELISA where reactivity of IL6gk3-2scFv from IL-6gk series with a recombinant IL-6, human serum albumin (HSA), AB blood type serum, monocyte chemoattractant protein-1 (MCP-1) and MIP-1 α (macrophage inflammatory protein-1 α) was measured.

FIG. 2 is a graph showing the results of BIA CORE where a binding affinity of IL6gk3-2 scFv with IL-6 was measured.

FIG. 3 is a graph showing the results that IL6gk3-2 scFv inhibited IL-6 dependent proliferation response of IL-6 dependent cell line KT-3

BEST MODE FOR CARRYING OUT THE INVENTION

From peripheral B lymphocytes taken from 20 healthy donors, cDNAs of each of immunoglobulin heavy (H) chain and light (L) chain were amplified by RT-PCR and combined together with a linker DNA to prepare single chain Fv (scFv) DNAs where the VH chain and VL chain DNAs from lymphocytes of healthy donors were in random combination.

The scFv DNAs were incorporated into phagemid vector pCANTABSE to prepare a scFv display phage library consisting of 10⁹ clones from healthy donors. This library was then combined with a human IL-6 immobilized on a solid phase and an anti-human IL-6 Fv display phage clone was recovered, concentrated and screened. As a result, the screened scFv clone (IL6gk3-2) produced scFv antibody that binds to a human IL-6.

The scFv antibody produced by the clone IL6gk3-2, in spite of being a single chain, specifically bound to a ligand (IL-6) with an affinity equivalent to the usual complete antibody.

The scFv antibody produced by the clone IL6gk3-2, when added to KT-3 cell line that proliferates in a human IL-6 dependent manner, inhibited IL-6 dependent proliferation response of said cell line in a concentration dependent manner.

The amino acid sequences of VH and VL chains of the above scFv clone having the inhibitory activity as well as the nucleotide sequences coding therefor are indicated in SEQ ID NOs: 1 and 2 (VH chain) and in SEQ ID NOs: 3 and 4 (VL chain), respectively.

In addition, the amino acid sequences of complementarity determining regions (CDR1 to CDR3), which are included in the above amino acid sequences, of VH and VL chains are shown below.

[VH chain]
CDR1
Lys Tyr Tyr Met Ala (SEQ ID NO: 5)

CDR2
Thr Ile Ser Asn Ser Gly Asp Ile (SEQ ID NO: 6)
Ile Asp Tyr Ala Asp Ser Val Arg
Gly

4

-continued

CDR3
Glu Tyr Phe Phe Ser Phe Asp Val (SEQ ID NO: 7)

[VL chain]
CDR1
Arg Ala Ser Gln Asp Ile Arg Asn (SEQ ID NO: 8)
Trp Val Ala

CDR2
Asp Gly Ser Ser Leu Gln Ser (SEQ ID NO: 9)

CDR3
Gln Gln Ser Asp Ser Thr Pro Ile (SEQ ID NO: 10)
Thr Phe

An antibody fragment having a variable region of either the VH chain or the VL chain as described above or variable regions of both VH and VL chains has a variable region of a human anti-human IL-6 antibody and strongly interacts with human IL-6 to thereby exert an inhibitory activity against the binding between IL-6 and an IL-6 receptor.

Although the VH chain and/or the VL chain of the human anti-human IL-6 antibody as disclosed herein were obtained in the form of scFv by the phage antibody technique, the present invention encompasses a human anti-human IL-6 antibody in the form of a complete molecule wherein the disclosed VH chain and/or VL chain are bound to a constant region of a human immunoglobulin, a human anti-human IL-6 antibody fragment such as Fab, Fab' or F(ab')₂, wherein the disclosed VH chain and/or VL chain are combined with a portion of a constant region of a human immunoglobulin, and other human anti-human IL-6 antibody fragment such as a human anti-human IL-6 single chain antibody (scAb) wherein scFv is bound to a constant region of a human immunoglobulin, as well as gene fragments encoding these antibodies and the antibody fragments. The present invention further encompasses a modified protein molecule wherein a high molecular weight modifying agent is bound to these antibody and antibody fragment protein molecules.

INDUSTRIAL APPLICABILITY

As described above, the human anti-human IL-6 antibody and the fragment molecules of said antibody according to the present invention may inhibit various immune responses induced by binding between IL-6 and an IL-6 receptor and hence may be used as an anti-inflammatory, analgesic agent or as a medicament for the treatment and prevention of autoimmune diseases.

Besides, the human anti-human IL-6 antibody and the fragment molecules of said antibody according to the present invention, in view of their property, may provide an immunological measurement for detection or measurement of IL-6 expressing cells in human peripheral blood or in muscles.

In addition, the human anti-human IL-6 antibody and the fragment molecules of said antibody according to the present invention may further provide many other applications when complexed with an immunoabsorbent consisting of an immunologically inactive adsorbent. For instance, IL-6 present in human peripheral blood may be purified with immunoaffinity chromatography. Such an immunoabsorbent complex may also be used for purification of IL-6 in a culture supernatant produced by culture cells transformed by the genetic recombination.

Besides, peptides of the variable region of the human anti-human IL-6 antibody of the present invention and derivatives of said peptides may provide a new means for isolating a peptide or an anti-idiotypic antibody that recognizes the human anti-human IL-6 antibody of the present invention.

US 7,482,436 B2

5

from a library. The obtained peptides and the anti-idiotypic antibodies and derivatives thereof are expected to be efficacious for treating acute inflammation due to IL-6 neutralization or autoimmune diseases (Vreugdenhil G. et al., *Rheumatol. Int.* 1990; 10(3): 127-30; Hirano T. et al., *Ric. Clin. Lab.* 1989 January-March, 19(1): 1-10).

The present invention is explained in more detail by means of the following Examples but should not be construed to be limited thereto.

EXAMPLE 1

Construction of Phage Library from Healthy Donors

Phage library was constructed as reported by J. D. Marks et al., *J. Mol. Biol.*, 222: 581-597, 1991 with some modification.

Lymphocytes were isolated from peripheral blood taken from 20 healthy donors by sedimentary centrifugation with Ficoll, washed thoroughly with PBS and then treated with ISOGEN (NIPPON GENE CO., LTD) to prepare a total RNA. The obtained total RNA was divided into four samples and from each of the samples were prepared cDNAs with primers specific to constant regions of either human IgG, IgM, κ chain or λ chain using first strand cDNA synthesis kit (Pharmacia biotech). Using each of the obtained cDNAs as a template, each of antibody V region genes were amplified by polymerase chain reaction (PCR) using primers specific to either of combinations of VH(γ or μ) and JH, V κ and J κ , or V λ and J λ , as described by Marks et al.

Then, VH (γ or μ) and V κ , and VH (γ or μ) and V λ , were linked together with a linker DNA by assembly PCR (McCafferty, J. et al.: *Antibody Engineering—A Practical Approach*, IRL Press, Oxford, 1996) to prepare single chain scFv DNAs. The obtained scFv DNAs were added with NotI and SfiI restriction sites using PCR, electrophoresed on agarose gel and then purified. The purified scFv DNAs were digested with the restriction enzymes NotI (Takara) and SfiI (Takara) and then cloned into phagemid pCANTAB5E (Pharmacia). The obtained phagemids pCANTAB5E where scFv DNA was bound were introduced into *E. coli* TG1 cells by electroporation for each of VH(γ)-V κ , VH(γ)-V λ , VH(μ)-V κ , and VH(μ)-V λ . From the number of the transformed TG1 cells, it was assessed that VH(γ)-V κ , VH(γ)-V λ , VH(μ)-V κ and VH(μ)-V λ exhibited diversity of 1.1×10^8 , 2.1×10^8 , 8.4×10^7 and 5.3×10^7 clones, respectively. With M13KO7 helper phage, phage antibodies were expressed on the transformed TG1 cells to prepare scFv display phage library derived from healthy donors.

EXAMPLE 2

Panning

Human IL-6 was dissolved in 1 mL 0.1M NaHCO₃ and the solution was incubated in 35 mm dish (Iwaki) at 4° C. overnight to immobilize IL-6. To the dish was added 0.5% gelatin/PBS for blocking at 20° C. for 2 hours and then the dish was washed six times with 0.1% Tween20-PBS. To the dish was then added 0.9 mL of the single chain antibody display phage solution (1×10^{12} tu/ml. of the antibody phage library derived from healthy donors) for reaction.

After washing the dish ten times with 0.1% Tween20-PBS, 1.0 mL glycine buffer (pH 2.2) was added to elute single chain antibody display phages bound to IL-6. After adjusting pH by adding 1M Tris (hydroxymethyl)-aminomethane-HCl, pH 9.1, the eluted phages were infected to *E. coli* TG1 cells at logarithmic growth phase. The infected TG1 cells were cen-

6

trifuged at 3,000×g for 10 minutes. Supernatant was removed, suspended in 200 μ L 2×YT culture medium, plated on SOBAG plate (SOB plate containing 2% glucose, 100 μ g/ml ampicillin) and then incubated overnight in an incubator at 30° C. The resulting colonies were suspended and recovered in a suitable amount of 2×YT culture medium with a scraper (Coastor).

The obtained TG1 solution (50 μ L) was inoculated on 30 mL 2×YT culture medium and rescued with a helper phage to prepare a phage library after screening.

For each of the phage libraries VH(γ)-V κ , VH(γ)-V λ , VH(μ)-V κ and VH(μ)-V λ derived from healthy donors, four pannings in total were performed with the IL-6 immobilized plate. After the fourth panning, any clone was extracted arbitrarily from the SOBAG plate. The scFv expression was confirmed, specificity was confirmed by IL-6 ELISA and a nucleotide sequence was analyzed.

EXAMPLE 3

IL-6 ELISA for Screening

For screening the isolated clones, ELISA was performed as follows: Human IL-6 and control proteins were immobilized on an ELISA plate for screening. Each 40 μ L/well of a human recombinant IL-6 (1.25 μ g/mL), a human serum albumin (HSA; 2.5 μ g/mL), a human monocyte chemoattractant protein 1 (MCP-1; 1.25 μ g/mL), a human MIP-1 α (macrophage inflammatory protein 1- α ; 1.25 μ g/mL) or a human AB blood type serum (1.25 μ g/mL) were placed in an ELISA plate (Nunc) which was kept standing at 4° C. for 16 hours for immobilization. The immobilized plate was added with 400 μ L/well of a PBS solution containing 0.5% BSA, 0.5% gelatin and 5% skimmed milk and was kept standing at 4° C. for 2 hours for blocking.

To the plate was added 40 μ L/well of sample solutions containing scFv display phage for reaction. The sample solutions were discarded and the plate was washed with a washing solution five times. The plate was reacted with biotin-labeled anti-M13 monoclonal antibody (Pharmacia biotech) and then with anti-mouse IgG antibody labeled with alkaline phosphatase (AP). After washing with a washing solution five times, the plate was added with 50 μ L/well of a developing solution of substrate, i.e. a PBS solution containing 1 g/mL p-nitrophenyl phosphate (Wako) and 10% diethanolamine (Wako), light-shielded, and developed at room temperature to 37° C. for 5 to 10 minutes. Absorbance at 405 nm was measured using Multiplate Autoreader NJ-2001 (Inter Med). As a result, all the clones assessed were confirmed to be specific to IL-6 (FIG. 1).

EXAMPLE 4

Sequence Analysis of Clones

A DNA nucleotide sequence of the isolated clones was determined for scFv gene VH and VL using Dye terminator cycle sequencing FS Ready Reaction kit (Applied Biosystems). As a result of ELISA and sequence analysis, the isolated clones were classified into four classes. Among these, the clone H.6gk3-2 had nucleotide sequences of VH and VL as shown in SEQ ID NOs: 1 and 3, respectively.

EXAMPLE 5

Expression and Recovery of scFv

A soluble scFv was expressed with *E. coli* HB2151, recovered from *E. coli* periplasm fraction and crudely purified. If

US 7,482,436 B2

7

further purification was necessary, affinity purification was performed with RAPAS Purification Module (Pharmacia Biotech). Purity of the purified scFv protein was confirmed by SDS-polyacrylamide gel electrophoresis and Western blotting where Etag epitope at the C-terminus of the scFv protein was targeted. For determination of a protein concentration of the purified scFv protein product, Protein Assay Kit (BIO-RAD) was used.

EXAMPLE 6

Affinity Measurement of Purified scFv by SPR

Using BIAcore (BIAcore), affinity of the purified scFv was measured by SPR. As a result, IL6gk3-2, the clone with the highest affinity among the isolated clones, was assessed to have 13×10^{-9} M of a dissociation constant (FIG. 2).

8

EXAMPLE 7

Effect on Proliferation Response of IL-6 Dependent Cell Line

The purified scFv was assessed for its inhibitory activity on IL-6 dependent proliferation response of cell line KT-3 that proliferates in an IL-6 dependent manner. KT-3 cells prepared at 2×10^4 cells/200 μ l/well were cultured for four days in the presence of 1.25 to 20 μ g/ml of the purified scFv from the clone IL6gk3-2 and IL-6 (80 pg/ml) and were assessed for DNA synthesis through thymidine intake. As a result, it was revealed that the scFv from the clone IL6gk3-2 inhibited proliferation response of KT-3 cells in a concentration dependent manner (FIG. 3).

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 10

<210> SEQ ID NO 1

<211> LENGTH 351

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

```

cag gtc aac tta agg gag tct ggg gga gac ttg gtc aag ccc gga ggg      48
Gln Val Asn Leu Arg Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly
                    5                      10                      15

tcc cta aga ctc tca tgt gca gcc tct gga ttc acc ttc aga aag tat      96
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Lys Tyr
                    20                      25                      30

tac atg gcc tgg atc cgc cag gct cca ggg aag ggg ccg gag tgg ctt      144
Tyr Met Ala Trp Ile Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp Leu
                    35                      40                      45

tca acc att agt aac agc ggt gat atc ata gac tat gca gac tct gtg      192
Ser Thr Ile Ser Asn Ser Gly Asp Ile Ile Asp Tyr Ala Asp Ser Val
                    50                      55                      60

agg ggc egg ttc tcc atc tcc agg gac aat gcc cag aag tca ctg tat      240
Arg Gly Arg Phe Ser Ile Ser Arg Asp Asn Ala Gln Lys Ser Leu Tyr
                    65                      70                      75

ctg caa atg acc tcc ctg aga ccc gac gac tgg gcc atc tat tac tgt      288
Leu Gln Met Thr Ser Leu Arg Pro Asp Asp Ser Ala Ile Tyr Tyr Cys
                    85                      90                      95

gcg agg gaa tat ttc ttt tct ttt gat gtg tgg ggc cga ggg aca atg      336
Ala Arg Glu Tyr Phe Phe Ser Phe Asp Val Trp Gly Arg Gly Thr Met
                    100                     105                     110

gtc acc gtc tcc tca
Val Thr Val Ser Ser
                    115

```

<210> SEQ ID NO 2

<211> LENGTH 117

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

```

Gln Val Asn Leu Arg Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly
                    5                      10                      15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Lys Tyr
                    20                      25                      30

```

US 7,482,436 B2

9

10

-continued

Tyr Met Ala Trp Ile Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp Leu
35 40 45

Ser Thr Ile Ser Asn Ser Gly Asp Ile Ile Asp Tyr Ala Asp Ser Val
50 55 60

Arg Gly Arg Phe Ser Ile Ser Arg Asp Asn Ala Gln Lys Ser Leu Tyr
65 70 75 80

Leu Gln Met Thr Ser Leu Arg Pro Asp Asp Ser Ala Ile Tyr Tyr Cys
85 90 95

Ala Arg Glu Tyr Phe Phe Ser Phe Asp Val Trp Gly Arg Gly Thr Met
100 105 110

Val Thr Val Ser Ser
115

<210> SEQ ID NO 3
<211> LENGTH: 324
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 3

gac atc gtg atg acc cag tct cca tct tct gtg tct gca tgg gtg gga 48
Asp Ile Val Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
5 10 15

gac aga gtc acc atc ttt tgt cgg gcg agt cag gat att agg aat tgg 96
Asp Arg Val Thr Ile Phe Cys Arg Ala Ser Gln Asp Ile Arg Asn Trp
20 25 30

gta gcc tgg tat caa cag aaa cca ggt gag gcc cct aaa tta ttg atc 144
Val Ala Trp Tyr Gln Gln Lys Pro Gly Glu Ala Pro Lys Leu Leu Ile
35 40 45

tat gat gga tgg agt ttg caa agt ggg gtc cca tca agg ttc agc ggc 192
Tyr Asp Gly Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

agt gga tct ggg aca gaa ttc act ctc aca atc agc agc ctg cag cct 240
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

gaa gat ttt gca act tac tac tgt caa cag agt gac agt acc cct att 288
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asp Ser Thr Pro Ile
85 90 95

acc ttc ggc caa ggg aca cga ctg gag att aaa cgt 324
Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg
100 105

<210> SEQ ID NO 4
<211> LENGTH: 108
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 4

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
5 10 15

Asp Arg Val Thr Ile Phe Cys Arg Ala Ser Gln Asp Ile Arg Asn Trp
20 25 30

Val Ala Trp Tyr Gln Gln Lys Pro Gly Glu Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Asp Gly Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asp Ser Thr Pro Ile

US 7,482,436 B2

11

12

-continued

	85		90		95
--	----	--	----	--	----

Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg
 100 105

<210> SEQ ID NO 5
 <211> LENGTH: 5
 <212> TYPE PRT
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <223> OTHER INFORMATION: CDR1 corresponding to amino acids No 31 to No
 35 in SEQ ID NO: 2

<400> SEQUENCE: 5

Lys Tyr Tyr Met Ala
 1 5

<210> SEQ ID NO 6
 <211> LENGTH: 17
 <212> TYPE PRT
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <223> OTHER INFORMATION: CDR2 corresponding to amino acids No 50 to No.
 66 in SEQ ID NO: 2

<400> SEQUENCE: 6

Thr	Ile	Ser	Asn	Ser	Gly	Asp	Ile	Ile	Asp	Tyr	Ala	Asp	Ser	Val	Arg	Gly
1				5					10						15	

<210> SEQ ID NO 7
 <211> LENGTH: 8
 <212> TYPE PRT
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <223> OTHER INFORMATION: CDR3 corresponding to amino acids No 99 to No
 106 in SEQ ID NO: 2

<400> SEQUENCE: 7

Glu	Tyr	Phe	Phe	Ser	Phe	Asp	Val
1				5			

<210> SEQ ID NO 8
 <211> LENGTH: 11
 <212> TYPE PRT
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <223> OTHER INFORMATION: CDR1 of corresponding to amino acids No 24 to
 No 34 in SEQ ID NO 4

<400> SEQUENCE: 8

Arg	Ala	Ser	Gln	Asp	Ile	Arg	Asn	Trp	Val	Ala
1				5				10		

<210> SEQ ID NO 9
 <211> LENGTH: 7
 <212> TYPE PRT
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <223> OTHER INFORMATION: CDR2 corresponding to amino acids No. 50 to No
 56 in SEQ ID NO: 4

<400> SEQUENCE: 9

Asp	Gly	Ser	Ser	Leu	Gln	Ser
1				5		

<210> SEQ ID NO 10
 <211> LENGTH: 10
 <212> TYPE PRT

US 7,482,436 B2

13

14

-continued-

<213> ORGANISM: Homo sapiens
 <220> FEATURE
 <223> OTHER INFORMATION: CDR3 corresponding to amino acids No 89 to No 98 in SEQ ID NO: 4
 <400> SEQUENCE 10
 Gln Gln Ser Asp Ser Thr Pro Ile Thr Phe
 1 5 10

The invention claimed is:

1. A gene fragment coding for a single chain Fv (hereinafter referred to as "scFv") of a human anti-human IL-6 antibody that binds to human IL-6 with a dissociation constant (K_D) of 1.0×10^{-8} M or less,

said gene fragment consisting of a gene fragment coding for a VH chain of said human anti-human IL-6 antibody bound to a gene fragment coding for a VL chain of said human anti-human IL-6 antibody;

wherein complementarity determining regions (CDR1 to CDR3) of said VH chain have the following amino acid sequences:

CDR1
 Lys Tyr Tyr Met Ala (SEQ ID NO: 5)

CDR2
 Thr Ile Ser Asn Ser Gly Asp Ile Ile (SEQ ID NO: 6)
 Asp Tyr Ala Asp Ser Val Arg Gly

CDR3
 Glu Tyr Phe Phe Ser Phe Asp Val (SEQ ID NO: 7)

and/or complementarity determining regions (CDR1 to CDR3) of said VL chain have the following amino acid sequences:

15 CDR1
 Arg Ala Ser Gln Asp Ile Arg Asn (SEQ ID NO: 8)
 Trp Val Ala

CDR2
 Asp Gly Ser Ser Leu Gln Ser (SEQ ID NO: 9)

20 CDR3
 Gln Gln Ser Asp Ser Thr Pro Ile (SEQ ID NO: 10)
 Thr Phe.

2. A gene fragment coding for a single chain Fv (hereinafter referred to as "scFv") of a human anti-human IL-6 antibody that binds to human IL-6 with a dissociation constant (K_D) of 1.0×10^{-8} M or less,

said gene fragment consisting of a gene fragment coding for a VH chain of said human anti-human IL-6 antibody bound to a gene fragment coding for a VL chain of said human anti-human IL-6 antibody,

wherein said VH chain has the amino acid sequence depicted in SEQ ID NO: 2 and/or said VL chain has the amino acid sequence depicted in SEQ ID NO: 4.

* * * * *